HIGHLIGHTS
- who: . et al. from the cancer, the perspective of the United StatesMokwon University, South Korea have published the research work: Atezolizumab plus platinum-based chemotherapy as rst-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis, in the Journal: (JOURNAL)
- what: Based on the perspective of the United States and China this study evaluated cost-effectiveness of atezolizumab plus chemotherapy for mUC patients in the first-line setting. The analysis had one notable feature in addition to its limitations.
- how: The authors conducted a comparative analysis from the perspectives of the United_States . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.